Emery R W, Arom K V, Nicoloff D M
Cardiac Surgical Associates, P.A., Minneapolis Heart Institute, MN, USA.
Semin Thorac Cardiovasc Surg. 1996 Jul;8(3):231-6.
Intensive in vitro and in vivo studies led to the clinical introduction of the St. Jude Medical (SJM) prosthesis in October 1977. Because of excellent clinical characteristics, handling, and durability, as well as the low incidence of clinically adverse events, the SJM valve has become the most commonly used prosthetic heart valve. In 1,431 patients undergoing aortic valve replacement during a 15-year period, the incidence of clinically adverse events, including thromboembolism, thrombosis, paravalvar leak, reoperation and anticoagulant-related hemorrhage, have been less than 0.8% per patient-year in both adult and pediatric patients. There have been no structural failures. The SJM prosthesis is an excellent device for the treatment of diseases of the aortic valve.
深入的体外和体内研究促使圣犹达医疗公司（SJM）的人工心脏瓣膜于1977年10月投入临床使用。由于其出色的临床特性、易操作性、耐用性以及临床不良事件的低发生率，SJM瓣膜已成为最常用的人工心脏瓣膜。在15年期间接受主动脉瓣置换术的1431例患者中，包括血栓栓塞、血栓形成、瓣周漏、再次手术和抗凝相关出血在内的临床不良事件发生率，在成人和儿童患者中均低于每年每患者0.8%。未发生结构故障。SJM人工心脏瓣膜是治疗主动脉瓣疾病的理想装置。
